UNITED THERAPEUTICS Corp

United Therapeutics develops therapies for individuals with serious diseases and unmet medical needs. The company's mission is to transform the treatment of rare diseases and increase the availability of transplantable organs using innovative organ manufacturing technologies. As a public benefit corporation, United Therapeutics aims to positively impact patients, employees, shareholders, and other stakeholders. Its public benefit purpose involves developing new pharmaceutical therapies and technologies to expand transplantable organ availability. In the United States, United Therapeutics markets and sells several commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI® (treprostinil) Inhalation Powder, Tyvaso® (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin® (treprostinil) Injection, Orenitram® (treprostinil) Extended-Release Tablets, and Adcirca® (tadalafil) Tablets. Tyvaso DPI and Nebulized Tyvaso are also approved by the U.S. Food and Drug Administration (FDA) for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, in the United States, the company markets and sells Unituxin® (dinutuximab) Injection, an oncology product approved by the FDA for high-risk neuroblastoma. Outside the United States, United Therapeutics generates revenue from sales of Nebulized Tyvaso, Remodulin, and Unituxin. The company also has products in development for PAH, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and other diseases with unmet medical needs.